Sign in to view content

High-Dose Anti-VEGF: Cross-Trial Analysis of Different Doses and Antagonists for the Treatment of Diabetic Macular Edema

Quan Dong Nguyen, MD, MSc, FARVO, FASRS

Video
Published 2019

Related

Economic Benefit of Higher Durability Anti-VEGF Agents in the Treatment of Neovascular Macular Degeneration
Sabin Dang, MD
Annual Meeting Talks
2023
Outcomes in Proliferative Diabetic Retinopathy Patients Lost to Follow-up After Panretinal Photocoagulation Versus Antivascular
Daniel Su, MD
Updates from the Field
2018
Defining a 'Strong' and 'Weak' Response to Anti-VEGF Treatment CI-DME: Retrospective Analysis of 3 DRCR Retina Network Clinical Trials
Sharon D. Solomon, MD
Annual Meeting Talks
2023

Category: Diabetic Retinopathy

See more